title: [Antimicrobial activity of cefteram comparison with other oral antibiotics].
abstract: Antimicrobacterial activities of cefteram (CFTM) against clinical isolates collected in 1988 were compared with those of new beta-lactams. 1. Antibacterial activities of CFTM against Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Branhamella catarrhalis isolated from acute respiratory tract infections were 8- to 16-fold higher than those of cefaclor (CCL). 2. Activities of cefixime (CFIX) were superior to those of CFTM against B. catarrhalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, but were inferior to CFTM against S. pneumoniae, S. pyogenes, Staphylococcus saprophyticus and Staphylococcus aureus. 3. Activities of cefuroxime were superior to those of CCL against each of the 4 tested bacterial species from acute respiratory tract infection and S. aureus by 4-fold, but were inferior to CFTM and CFIX against most of Gram-negative rods. 4. Sultamicillin (SBTPC) is considered to have an activity to inhibit beta-lactamase, but its MICs did not exceed the MICs of ampicillin by itself. SBTPC showed poor antibacterial activities against methicillin-resistant S. aureus (MRSA). Considering these observations, it is apparent that we are faced with a variety of factors in selecting antibiotics for best results.
authors.affiliation: Research Department, Tokyo Clinical Research Center.
authors.forename: K
authors.initials: K
authors.lastname: Deguchi
authors.forename: N
authors.initials: N
authors.lastname: Yokota
authors.forename: M
authors.initials: M
authors.lastname: Koguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Nakane
authors.forename: Y
authors.initials: Y
authors.lastname: Fukushima
authors.forename: S
authors.initials: S
authors.lastname: Fukayama
authors.forename: Y
authors.initials: Y
authors.lastname: Nishimura
authors.forename: S
authors.initials: S
authors.lastname: Oda
authors.forename: S
authors.initials: S
authors.lastname: Tanaka
authors.forename: K
authors.initials: K
authors.lastname: Sato
mesh_terms: D000667:Ampicillin / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D015281:Cefmenoxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000494:pharmacology; D006801:Humans; D008712:Methicillin / Q000494:pharmacology; D010403:Penicillin Resistance; D012141:Respiratory Tract Infections / Q000382:microbiology; D012874:Skin Diseases, Infectious / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects; D013407:Sulbactam / Q000494:pharmacology; D014552:Urinary Tract Infections / Q000382:microbiology
chemical_list: C035444:sultamicillin; C049493:cefteram; D000667:Ampicillin; D015281:Cefmenoxime; D008712:Methicillin; D013407:Sulbactam